Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation  Malathy Appasamy,

Slides:



Advertisements
Similar presentations
Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States  David B. Seifer, M.D., Valerie.
Advertisements

Yuqian Cui, M. D. , Ph. D. , Yuhua Shi, M. D. , Ph. D. , Linlin Cui, M
Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study  Thi.
Age at menarche: a predictor of diminished ovarian function?
Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing.
The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition  Lorraine Dennerstein,
Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization–intracytoplasmic.
No difference in cycle pregnancy rate and in cumulative live-birth rate between women with surgically treated minimal to mild endometriosis and women.
Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase  Michael von Wolff, M.D., Christian J. Thaler,
Michael M. Alper, M.D.  Fertility and Sterility 
Analysis of follicular fluid and serum markers of oxidative stress in women with infertility related to endometriosis  Laura Prieto, M.D., Juan F. Quesada,
Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis 
Janet Kwee, M. D. , Roel Schats, M. D. , Ph. D. , Joseph McDonnell, M
Administration of a gonadotropin-releasing hormone antagonist during the 3 days before the initiation of the in vitro fertilization/intracytoplasmic sperm.
Hepatitis and reproduction
Follicular fluid anti-Müllerian hormone and inhibin B concentrations: comparison between gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist.
Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome 
Robot-assisted laparoscopy for infertility treatment: current views
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization.
Testosterone use in the male infertility population: prescribing patterns and effects on semen and hormonal parameters  Mary K. Samplaski, M.D., Yasir.
Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D
Anti-Müllerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm.
A comparison of blood spot vs
The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility  Alexander M. Quaas, M.D.,
Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with.
Mikkel Rosendahl, M. D. , Claus Yding Andersen, D. M. Sc
Oocyte cryopreservation
Follicular fluid and serum levels of Inhibin A and pregnancy-associated plasma protein A in patients undergoing IVF  Jiri Moos, Ph.D., Vanda Filova, Ph.D.,
Deleterious effect of tobacco on IVF outcome and ovarian reserve as reflected by serum anti mullerian hormone (AMH)  P. Barriere, T. Freour, D. Masson,
Evaluation of serum antimullerian hormone and inhibin B concentrations in the differential diagnosis of secondary oligoamenorrhea  Hang Wun Raymond Li,
Robert F. Casper, M.D.  Fertility and Sterility 
Mieke Carine Wim Eeckhaut, Ph.D.  Fertility and Sterility 
Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility  Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,
Mitchell P. Rosen, M. D. , Erica Johnstone, M. D. , Charles E
Introduction Fertility and Sterility
Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D. 
Treatment of male idiopathic infertility with recombinant human follicle-stimulating hormone: a prospective, controlled, randomized clinical study  Carlo.
Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection  Dorothea M.
Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,
Follicular-fluid neurotrophin levels in women undergoing assisted reproductive technology for different etiologies of infertility  Erkan Buyuk, M.D.,
Irene V. Lambrinoudaki, M. D. , Areti Augoulea, M. D. , George E
Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Nargund, M.D. 
Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D
Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin  Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.
Human granulosa-lutein cell in vitro production of progesterone, inhibin A, inhibin B, and activin A are dependent on follicular size and not the presence.
L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing 
The serum follicle-stimulating hormone-to-luteinizing hormone ratio at the start of stimulation with gonadotropins after pituitary down-regulation is.
Fertility and Sterility: an evaluation
Anuja Dokras, M. D. , Ph. D. , Antonia Habana, M. D. , Juan Giraldo, M
Ethnicity or environment: effects of migration on ovarian reserve among Bangladeshi women in the United Kingdom  Khurshida Begum, M.B.B.S., Ph.D., Shanthi.
Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing.
Association of endometriosis with body size and figure
Effects of gonadotropin-releasing hormone agonist/recombinant follicle-stimulating hormone versus gonadotropin-releasing hormone antagonist/recombinant.
Current evaluation of amenorrhea
Inappropriate gonadotropin secretion in polycystic ovary syndrome
Serum anti-Mullerian hormone dynamics during stimulated cycles by aromatase inhibitor anastrozole and clomiphene citrate in women with infertility  H.-H.
Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists 
Serum inhibin A, inhibin B, pro-αC, and activin A levels in women with idiopathic premature ovarian failure  Winfried Munz, M.D., Mohamed Eid Hammadeh,
Comparing anti-Müllerian hormone (AMH) and follicle-stimulating hormone (FSH) as predictors of ovarian function  David H. Barad, M.D., M.S., Andrea Weghofer,
Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study  Ahmed Badawy, M.D., Aboubakr.
Egg production predicts a doubling of in vitro fertilization pregnancy rates even within defined age and ovarian reserve categories  Melissa C. Yih, M.D.,
Cem Fiçicioǧlu, M. D. , Tayfun Kutlu, M. D. , Elif Baglam, M. D
In vitro sildenafil citrate use as a sperm motility stimulant
Soluble HLA-G in the peritoneal fluid of women with endometriosis
Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation  Reshef.
Ovarian follicular volume and follicular surface area are better indicators of follicular growth and maturation, respectively, than is follicular diameter 
A novel “delayed start” protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders  Hakan Cakmak, M.D., Nam D. Tran,
A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three- dimensional ultrasound determinants of ovarian reserve in the prediction.
Comparisons of inhibin B versus antimüllerian hormone in poor ovarian responders undergoing in vitro fertilization  Rongrong Tan, M.M.Sc., Danhua Pu,
Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated.
Presentation transcript:

Evaluation of the relationship between follicular fluid oxidative stress, ovarian hormones, and response to gonadotropin stimulation  Malathy Appasamy, M.R.C.O.G., Eric Jauniaux, M.D., Ph.D., M.R.C.O.G., Paul Serhal, M.R.C.O.G., Ahmed Al-Qahtani, Ph.D., Nigel P. Groome, Ph.D., Shanthi Muttukrishna, Ph.D.  Fertility and Sterility  Volume 89, Issue 4, Pages 912-921 (April 2008) DOI: 10.1016/j.fertnstert.2007.04.034 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Preovulatory ovarian hormones and TAC in the different etiologies of infertility. 1, male-factor infertility (n = 56); 2, unexplained infertility (n = 36); 3, tubal factor infertility (n = 16); 4, PCOS (n = 15); and 5, endometriosis (n = 7). Data are presented as mean ± SEM, ★P<.05, ★★P<.001. Closed bars represent serum values, and open bars represent FF values. (A) Serum and FF AMH (ng/mL) in the different etiologies of infertility. (B) Serum (pg/mL) and FF (ng/mL) inhibin A in the different etiologies of infertility. (C) Serum (pg/mL) and FF inhibin B (ng/mL) in the different etiologies of infertility. (D) Follicular fluid activin A (ng/mL) in the different etiologies of infertility. (E) Serum (pg/mL) and FF (ng/mL) E2 in the different etiologies of infertility. (F) Plasma and FF TAC (μmol/L) in the different etiologies of infertility. Fertility and Sterility 2008 89, 912-921DOI: (10.1016/j.fertnstert.2007.04.034) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Preovulatory ovarian hormones and TAC in the different responder groups: 1, poor responders (<5 oocytes; n = 11); 2, normal responders (5–10 oocytes; n = 57); and 3, good responders (>10 oocytes; n = 62) ★P<.05, ★★P<.001. Closed bars represent serum values, and open bars represent FF values. (A) Serum and FF AMH (ng/mL) in the different responder groups. (B) Serum (pg/mL) and FF (ng/mL) inhibin A in the different responder groups. (C) Serum (pg/mL) and FF (ng/mL) inhibin B in the different responder groups. (D) Follicular-fluid activin A (ng/mL) in the different responder groups. (E) Serum (pg/mL) and FF (ng/mL) E2 in the different responder groups. (F) Plasma and FF TAC (μmol/L) in the different responder groups. Fertility and Sterility 2008 89, 912-921DOI: (10.1016/j.fertnstert.2007.04.034) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions